1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Immunovia AB (publ)

Immunovia AB (publ)

IMMNOV.ST
Immunovia AB (publ)SE flagStockholm Stock Exchange
0.20
SEK
+0.02
- -
69.87MMarket Cap
Immunovia AB (publ)
IMMNOV.ST
(Stockholm Stock Exchange)

Recent

price

0.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.04
0.01
0.01
- -
- -
0.01
0.01
0.01
0.01
0.02
0.03
0.01
- -
- -
Revenue per Share
-0.05
-0.29
-0.23
-0.35
-0.96
-1.67
-2.1
-2.45
-2.47
-2.66
-6.18
-0.93
-0.42
-0.22
Basic EPS, GAAP
-0.07
-0.37
-0.83
-1.02
-1.64
-2.35
-2.35
-2.83
-2.8
-2.81
-2.96
-1.17
-0.24
-0.16
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.01
-0.12
-0.55
-0.77
-1.64
-3.17
-5.1
-7.13
-9.19
-11.85
-21.1
-13.68
-3.66
-2.6
Book Value per Share
0.04
0.98
2.19
6.15
4.23
7.73
4.87
7.8
4.54
1.75
1.29
0.12
0.17
0.08
Tangible Book Value per Share
31
31
32
42
47
52
55
60
63
63
50
83
344
492
Basic Weighted Avg Shares
1
- -
- -
- -
- -
- -
- -
- -
1
1
2
1
1
1
Sales/Revenue/Turnover
-136.91
-2,543.33
-3,623.4
-8,466.97
-30,597.15
-26,496.1
-32,120.79
-37,203.87
-19,756.04
-16,699.48
-18,832.7
-11,765.52
-11,744.82
-8,695.65
Operating Margin (%)
- -
- -
- -
1
1
3
8
10
19
25
142
13
2
1
Depreciation Expense
-2
-9
-7
-15
-45
-87
-115
-146
-156
-168
-309
-77
-146
-107
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-135.45
-2,466.58
-3,598.41
-8,304.88
-30,364.72
-25,987.69
-32,168.82
-40,340.61
-18,479.38
-14,680.52
-19,646.92
-8,221.37
-21,301.46
-11,594.78
Profit Margin (%)
1
30
69
254
190
383
241
441
264
92
51
13
65
39
Working Capital
- -
- -
- -
- -
- -
- -
33
28
27
33
2
- -
- -
- -
LT Debt
5
36
84
277
237
462
358
599
434
244
67
12
65
47
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
20
1
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
394
673
673
Market Capitalization
121
91
85

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
29
80
59
Cash, Cash Equivalents & STI
27
77
56
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
46
16
19
Payables & Accruals
- -
- -
- -
ST Debt
20
1
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
58.52%
45.88%
455.97%
Free Cash Flow
17.82%
-11.79%
-13.22%
Net Income, GAAP
57.18%
22.81%
90.64%
Sales/Revenue/Turnover
24.16%
27.81%
-26.42%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.05
-0.44
-0.44
0.02
-0.93
2025
-0.19
-0.11
-0.08
-0.03
-0.42
2026
-0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Devyser Diagnostics AB (publ) (DVYSR.ST)
Genetron Holdings Limited (GTH)
Pacific Edge Limited (PEB.NZ)
Applied DNA Sciences, Inc. (APDN)
CelLBxHealth plc (ANPCY)
Thermo Fisher Scientific Inc. (TMO.NE)
Business
Immunovia AB (publ) (IMMNOV.ST) is a Sweden-based diagnostic company that develops and commercializes blood tests for early detection of pancreatic cancer and autoimmune diseases using its proprietary IMMray platform, which employs antibody biomarker microarray analysis, machine learning, and bioinformatics to identify disease-specific biomarker signatures; core products include the recently launched PancreaSure blood test for high-risk pancreatic cancer detection at Stages 1-2 with 87.9% sensitivity in late-stage cases and 97.7% specificity, the earlier IMMray PanCa-d laboratory-developed test offered through U.S. and Swedish Dx laboratories, and diagnostic tools like IMMray SLE-d for lupus differentiation. Founded in 2007 and headquartered in Lund, Sweden, with clinical labs and key operations in the U.S. including North Carolina and Massachusetts, the company targets high-risk patients through surveillance programs at leading centers such as University of Pennsylvania, Northwestern University, Inova Schar Cancer Institute, and Hackensack Meridian Health. Recent developments encompass the commercial launch of PancreaSure on September 2, 2025, with adoption by 10 top U.S. pancreatic cancer centers and key opinion leader advocacy; a SEK 100 million rights issue completed in October 2025 raising net proceeds of SEK 90.3 million to fund commercialization, clinical utility studies, and Medicare reimbursement efforts targeting full coverage by 2026 at a preliminary rate of $897; a licensing agreement with Proteomedix for manufacturing independence and cost reduction; CAP accreditation for its North Carolina lab; peer-reviewed CLARITI study publication in Gastroenterology; and a bridge loan of SEK 20 million ahead of the rights issue, alongside NIH-funded prospective trials and a three-phase strategy shifting to revenue growth in 2027.